

EXECUTIVE SUMMARY

NeuroOne Medical Technologies Corporation (NMTC) is a publicly-held development stage company (OTC:NMTC) focused on improving surgical options and outcomes for patients suffering with epilepsy, Parkinson’s Disease, and other brain-related neurological disorders by offering new and advanced diagnostic and therapeutic technologies.

SUMMARY OF FINANCIAL DATA

Stock Symbol: NMTC

Shares Outstanding: 7,864,994

Market Cap: \$33.03 Million

Shares in Float (estimate): 400,000

Price and volume quotes from Yahoo! Finance and other reliable sources.

INVESTMENT HIGHLIGHTS

- *Substantial* and *well-defined* market opportunity
- *Disruptive* and *innovative* technologies which:
 - Address a **significant** and **unmet** need
 - Offer the potential of substantially *improved outcomes*
 - Opportunity to *lower costs*
- The majority of NMTC’s products require only U.S. FDA 510(k) clearance
- World-class Scientific Advisory Board members from highly-recognized centers of excellence
- Robust and growing intellectual property portfolio
- Experienced management team and Board of Directors

MANAGEMENT

Dave Rosa, President and CEO — Three decades of experience in the medical device industry spanning a variety of technologies and products. Background includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical. Named inventor on multiple medical device patents.

Mark Christianson, VP of Business Development and Marketing — In excess of 15 years of executive sales, sales management, and marketing experience with development stage and other companies.

Tom Bachinski, Chief Development Officer — Thirty years of experience in research and development, engineering, and product development of neuro-stimulation devices, sensors and controls in the neurological market. Named inventor on 73 patents.

SCIENTIFIC ADVISORY BOARD

Greg Worrell, MD, PhD — Mayo Clinic

Jamie Van Gompel, MD — Mayo Clinic

Jorge Gonzalez, MD, PhD — Cleveland Clinic

Greg Esper, MD, MBA — Emory University

Justin Williams, PhD — University of Wisconsin

Disclaimer: This fact sheet contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are valid only as of today, and we disclaim any obligation to update this information. Actual results may differ significantly from management’s expectations.

EPILEPSY PREVALENCE AND INCIDENCE

- 3.47 million people in the U.S. were living with epilepsy in 2015
- One in 26 Americans will develop epilepsy in their lifetime, and almost 150,000 people in the U.S. develop epilepsy every year
- Six million people in Europe and 50 million people worldwide have epilepsy

PRODUCTS DEVELOPED AND IN DEVELOPMENT

PRODUCT	DESCRIPTION
Thin-Film Cortical Electrode (Dx)	Advanced thin-film technology placed on the brain surface to record irregular activity; high signal clarity improves diagnosis for better outcomes. Includes disposable connection cable saving hospitals time and cost.
Minimally Invasive (MI) Cortical Electrode Delivery System (Dx)	Enables deployment of Thin-Film Cortical Electrode beneath the skull via a small (1-1.5”) hole, versus a standard large craniotomy. Currently, only NMTC technology can enable this technique.
sEEG Depth Electrode (Dx)	A probe format of the Thin-Film Cortical Electrode inserted robotically into the brain for MI detection and recording of irregular brain activity.
Combination Diagnostic + Ablation Depth Electrode (Dx & Tx)	Expanding NMTC’s sEEG Depth Electrode technology, this product will perform both <i>diagnostic</i> and <i>ablation (therapeutic)</i> functions during a single MI surgical procedure, rather than two separate procedures.
Deep Brain Stimulation (DBS) System (Tx)	Permanent implant utilizing our core thin-film technology attributes to offer more effective electrode placement, improved responsive stimulation algorithms, and reduced brain inflammation.
MRI Compatible Surface Electrodes (Dx)	Non-invasive recording of brain activity without the need to remove and replace electrodes for needed MRI

DIFFERENTIATED CORE TECHNOLOGY & KEY ADVANTAGES

Portfolio is largely based on patented thin-film, brain friendly, flexible circuit technology. High signal clarity can detect microseizures and single neuron activity improving diagnoses for better treatment outcomes while significantly reducing hospital length of stay. Current surgical options for epilepsy have opportunities for improvement as they require multiple, highly invasive, painful procedures which carry significant risks, such as infection, and require lengthy hospitalization. Products based on NeuroOne’s technology may improve diagnostic capabilities, enable minimally invasive approaches, and offer single-procedure diagnostic and therapeutic options, all which are intended to improve patient outcomes and reduce costs.

REGULATORY APPROVAL

NMTC expects to have a low risk path to regulatory approval as a majority of its products require only U.S. FDA 510(k) clearance resulting in shorter approval timelines and reduced costs vs. products requiring PMAs.

MARKET OPPORTUNITY (FOR EPILEPSY ONLY)

There are ~188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current NMTC market opportunity is approximately \$525.6 million. Fully penetrated, the addressable market is estimated to be approximately \$14.9 billion.